GlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, to a new bioscience cluster that it says could become one of the largest in Europe.

GSK's recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the first partners have joined the initiative.

Walmsley’s efforts ruffled feathers, and morale was initially low at GSK’s research hub in Stevenage, north of London. In an ...